Literature DB >> 23063566

Synthesis and biological evaluation of new 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles as PI3Kα inhibitors.

Amélie Bruel1, Cédric Logé, Marie-Ludivine de Tauzia, Myriam Ravache, Rémy Le Guevel, Christiane Guillouzo, Jean-François Lohier, Jana Sopkova-de Oliveira Santos, Olivier Lozach, Laurent Meijer, Sandrine Ruchaud, Hélène Bénédetti, Jean-Michel Robert.   

Abstract

A series of novel 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles was synthesized through a newly developed approach. All these compounds were evaluated against DYRK1A, CDK5 and PI3Kα and showed promising inhibitory activities against PI3Kα with most IC(50) values in the micromolar range. Among them, compound 18 was strongly considered as the most interesting compound with an IC(50) value of 0.091 μM. This series exhibited also significant anti-proliferative effects in various human cancer cell lines including those resulting in activation of the PI3K pathway.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23063566     DOI: 10.1016/j.ejmech.2012.09.001

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  7 in total

1.  Targeted treatments for metastatic esophageal squamous cell cancer.

Authors:  Antonia Digklia; Ioannis A Voutsadakis
Journal:  World J Gastrointest Oncol       Date:  2013-05-15

Review 2.  Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors.

Authors:  Mark E Welker; George Kulik
Journal:  Bioorg Med Chem       Date:  2013-05-09       Impact factor: 3.641

3.  Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.

Authors:  Michael Tarpley; Helen O Oladapo; Dillon Strepay; Thomas B Caligan; Lhoucine Chdid; Hassan Shehata; Jose R Roques; Rhashad Thomas; Christopher P Laudeman; Rob U Onyenwoke; David B Darr; Kevin P Williams
Journal:  Eur J Pharm Sci       Date:  2021-03-27       Impact factor: 5.112

4.  Synthesis and biological evaluation of new 3(2H)-pyridazinone derivatives as non-toxic anti-proliferative compounds against human colon carcinoma HCT116 cells.

Authors:  Zeynep Özdemir; Semra Utku; Bijo Mathew; Simone Carradori; Giustino Orlando; Simonetta Di Simone; Mehmet Abdullah Alagöz; Azime Berna Özçelik; Mehtap Uysal; Claudio Ferrante
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

5.  Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies.

Authors:  Pillaiyar Thanigaimalai; Sho Konno; Takehito Yamamoto; Yuji Koiwai; Akihiro Taguchi; Kentaro Takayama; Fumika Yakushiji; Kenichi Akaji; Shen-En Chen; Aurash Naser-Tavakolian; Arne Schön; Ernesto Freire; Yoshio Hayashi
Journal:  Eur J Med Chem       Date:  2013-08-09       Impact factor: 6.514

6.  Synthesis, Cytotoxicity and Anti-Proliferative Activity Against AGS Cells of New 3(2H)-Pyridazinone Derivatives Endowed with a Piperazinyl Linker.

Authors:  Mehmet Abdullah Alagöz; Zeynep Özdemir; Mehtap Uysal; Simone Carradori; Marialucia Gallorini; Alessia Ricci; Susi Zara; Bijo Mathew
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-25

7.  Discovery of hydrazide-based pyridazino[4,5-b]indole scaffold as a new phosphoinositide 3-kinase (PI3K) inhibitor for breast cancer therapy.

Authors:  Ahmed A M Sarhan; Ahmed T A Boraei; Assem Barakat; Mohamed S Nafie
Journal:  RSC Adv       Date:  2020-05-21       Impact factor: 4.036

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.